Shares of Dr Lal Path Labs surged by 3.46%, rising ₹112.75 to trade at ₹3,368.45 on the NSE at 9:16 AM. The stock’s upward movement follows the release of strong Q2 FY25 earnings and positive brokerage updates.
Dr Lal Path Labs reported an 18% year-on-year increase in net profit, reaching ₹129 crore for Q2 FY25. This follows a robust Q1 performance where net profit grew by 28% to ₹106 crore, alongside an 11.3% rise in revenue. Brokerages have also reacted positively, with UBS maintaining a buy call and Goldman Sachs adjusting its target based on these earnings.
Investor sentiment remains buoyed by the company’s consistent growth trajectory, as reflected in both Q1 and Q2 performances, and ongoing improvements in patient volumes.
Disclaimer: This article is for informational purposes only and does not constitute financial advice. Please consult a qualified financial advisor before making any investment decisions.
